VANANTWERP
v.
GLAXOSMITHKLINE, LLC
AI-generated. These summaries, headnotes, and key points are machine-generated and may contain errors or omissions. Always verify against the full opinion text below. Not legal advice.
Actions involving common questions of fact regarding Zantac (ranitidine) products are transferred to the Southern District of Florida for coordinated pretrial proceedings under 28 U.S.C. § 1407.
[1] Under 28 U.S.C. …
Previewing 1 of 1 headnotes on this case. FLexlaw’s editorially structured points of law — every proposition, pinpointed — are reserved for members.
Join FLexlaw to unlock all legal intelligenceThe Judicial Panel on Multidistrict Litigation previously transferred 456 Zantac-related civil actions to the Southern District of Florida beginning i…
The full statement of facts, procedural history, and disposition for this case are member content.
Join FLexlaw to unlock all legal intelligence© FLexlaw, Inc. — AI-generated enrichments are proprietary. All rights reserved.
Explore caselaw by topic → Browse Products Liability cases and more on FLexlaw
IN RE: ZANTAC (RANITIDINE) PRODUCTS LIABILITY LITIGATION MDL No. 2924
cmomenre nine file (SEE ATTACHED SCHEDULE) ew eee dt Adams SS Oct 17, 2024" CONDITIONAL TRANSFER ORDER (CTO —128)
On February 6, 2020, the Panel transferred 12 civil action(s) to the United States District Court for the Southern District of Florida for coordinated or consolidated pretrial proceedings pursuant to 28 U.S.C. § 1407. See 437 F. Supp. 3d 1368 (J.P.M.L. 2020). Since that time, 444 additional action(s) have been transferred to the Southern District of Florida. With the consent of that court, all such actions have been assigned to the Honorable Robin L. Rosenberg. It appears that the action(s) on this conditional transfer order involve questions of fact that are common to the actions previously transferred to the Southern District of Florida and assigned to Judge Rosenberg. Pursuant to Rule 7.1 of the Rules of Procedure of the United States Judicial Panel on Multidistrict Litigation, the action(s) on the attached schedule are transferred under 28 U.S.C. § 1407 to the Southern District of Florida for the reasons stated in the order of February 6, 2020, and, with the consent of that court, assigned to the Honorable Robin L. Rosenberg. This order does not become effective until it is filed in the Office of the Clerk of the United States District Court for the Southern District of Florida. The transmittal of this order to said Clerk shall be stayed 7 days from the entry thereof. If any party files a notice of opposition with the Clerk of the Panel within this 7-day period, the stay will be continued until further order of the Panel.
Inasmuch as no objection is FOR THE PANEL: ric, time, the ——_— Oct 17, 2024 sell Q. Kock ent ch initeD STATES MULTIDISTRICT LITIGATION Marcella R. Lockert Acting Clerk of the Panel
IN RE: ZANTAC (RANITIDINE) PRODUCTS LIABILITY LITIGATION MDL No. 2924
SCHEDULE CTO-128 — TAG-ALONG ACTIONS
DIST DIV. C.A.NO. CASE CAPTION
CALIFORNIA NORTHERN
CAN 3 24-0696 Lopp v. GlaxoSmithKline, LLC et al CAN 3 24-06964 Vanantwerp v. GlaxoSmithKline, LLC et al CAN 3 2406959 Dondero v. GlaxoSmithKline, LLC et al CAN 3 2406962 Stanley v. GlaxoSmithKline, LLC et al CAN 3 24—06965 Blue v. GlaxoSmithKline, LLC et al